| 1 |
Brian E, Henderson, Norman H, Lee, Victoria Seewaldt, Hongbing Shen (2012). The influence of race and ethnicity on the biology of cancer. Nature Reviews Cancer, 12, 648-53.
DOI
|
| 2 |
Bergethon K, Shaw AT, Ou SH, et al (2012). ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 30, 863-70.
DOI
|
| 3 |
Bergethon K, Shaw AT, Ou SH, et al (2012). ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 30, 863-70.
DOI
|
| 4 |
Bell DW (2010). Our changing view of the genomic landscape of cancer. J Pathol, 220, 231-43.
|
| 5 |
Campbell PJ, Yachida S, Mudie LJ, et al (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 1109-13.
DOI
|
| 6 |
Chaft JE, Arcila ME, Paik PK, et al (2012). Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma: rationale for comprehensive mutation profiling. Mol Cancer Ther, 11, 485-91.
DOI
|
| 7 |
Ding L, Wendl MC, Koboldt DC, Mardis ER (2010). Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet, 19, 188-96.
DOI
|
| 8 |
Ding L, Ellis MJ, Li S, et al (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature, 464, 999-1005.
DOI
|
| 9 |
DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41
DOI
|
| 10 |
Ding L, Getz G, Wheeler DA, et al (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 455, 1069-75.
DOI
|
| 11 |
Ley TJ, Mardis ER, Ding L, et al (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature, 456, 66-72.
DOI
|
| 12 |
Lindeman NI, Cagle PT, Beasley MB, et al (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol, 8, 823-59.
DOI
ScienceOn
|
| 13 |
Lee W, Jiang Z, Liu J, et al (2010). The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature, 465, 473-7.
DOI
ScienceOn
|
| 14 |
Ley TJ, Ding L, Walter MJ, et al (2010). DNMT3A mutations in acute myeloid leukemia. N Engl J Med, 363, 2424-33.
DOI
|
| 15 |
Larsen JE, Minna JD (2011). Molecular biology of lung cancer: clinical implications. Clin Chest Med, 32, 703-40.
DOI
|
| 16 |
Morozova O, Marra MA (2008). Applications of next-generation sequencing technologies in functional genomics. Genomics, 92, 255-64.
DOI
|
| 17 |
Maher CA, Palanisamy N, Brenner JC, et al (2009). Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci USA, 106, 12353-8.
DOI
|
| 18 |
Meyerson M, Gabriel S, Getz G (2010). Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet, 11, 685-96.
DOI
|
| 19 |
Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 361, 1058-66.
DOI
ScienceOn
|
| 20 |
Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
DOI
|
| 21 |
Shah SP, Kobel M, Senz J, et al (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med, 360, 2719-29.
DOI
|
| 22 |
Sos ML, Koker M, Weir BA, et al (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69, 3256-61.
DOI
ScienceOn
|
| 23 |
Shaw AT, Camidge DR, Engelman JA (2012). Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboringROS1 gene rearrangement. J Clin Oncol, 30, 7508.
|
| 24 |
Sasaki T, Rodig SJ, Chirieac LR, et al (2010). The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 46, 1773-80.
DOI
|
| 25 |
Samuels Y, Wang Z, Bardelli A, et al (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 554.
DOI
ScienceOn
|
| 26 |
Trigka EA, Levidou G, Saetta AA, et al (2013). A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep, 30, 623-36.
|
| 27 |
Thomas A, Rajan A, Lopez-Chavez A, et al (2013). From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol, 24, 577-85.
DOI
|
| 28 |
Tang H, Xiao G, Behrens C, et al (2013). A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res, 19, 1577-86.
DOI
|
| 29 |
Takeda H, Takigawa N, Ohashi K, et al (2013). Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res, 319, 417-23.
DOI
|
| 30 |
Engelman JA, Zejnullahu K, Gale CM, et al (2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res, 67, 11924-32.
DOI
|
| 31 |
Field JK, Brambilla C, Caporaso N, et al (2002). Consensus statements from the second international lung cancer molecular biomarkers workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol, 21, 369-73.
|
| 32 |
Gandara DR, Mack PC, Li T, et al (2009). Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer, 10, 392-4.
DOI
|
| 33 |
Gandara DR, Li T, Lara PN, Jr, et al (2012). Algorithm for codevelopment of new drug-predictive biomarker combinations: Accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer, 13, 321-5.
DOI
|
| 34 |
Gonzales AJ, Hook KE, Althaus IW, et al (2008). Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther, 7, 1880-9.
DOI
|
| 35 |
Gainor JF, Shaw AT (2013). Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist, 18, 865-75.
DOI
|
| 36 |
Govindan R, Hammerman PS, Hayes DN, et al (2012). Comprehensive genomic characterization of squamous cell carcinoma of the lung. J Clin Oncol, 30,453s. abstr 7006.
DOI
|
| 37 |
Griffith M, Griffith OL, Mwenifumbo J, et al (2010). Alternative expression analysis by RNA sequencing. Nat Methods, 7, 843-7.
DOI
|
| 38 |
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
DOI
|
| 39 |
Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.
DOI
|
| 40 |
Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol, 11, 121-8.
DOI
|
| 41 |
Marsit CJ, Zheng S, Aldape K, et al (2005). PTEN expression in non-small cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36, 768-76.
DOI
|
| 42 |
National Comprehensive Cancer Network: Non-Small Cell Lung Cancer. Version 1.2015. NCCN clinical practice guidelines in oncology. http://www.nccn.com.
|
| 43 |
Ozsolak F, Milos PM (2011). RNA sequencing: advances, challenges and opportunities. Nat Rev Genet, 12, 87-98.
DOI
|
| 44 |
Paik PK, Hasanovic A, Wang L, et al (2012). Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol, 30, 481s. abstr 7505.
|
| 45 |
Pleasance ED, Cheetham RK, Stephens PJ, et al (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463, 191-6.
DOI
ScienceOn
|
| 46 |
Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, 73.
DOI
ScienceOn
|
| 47 |
Pao W, Girard N (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12, 175-80.
DOI
|
| 48 |
Voelkerding KV, Dames SA, Durtschi JD (2009). Nextgeneration sequencing: from basic research to diagnostics. Clin Chem, 55, 641-58.
DOI
|
| 49 |
US Food and Drug Administration: FDA approves Xalkori with companion diagnostic for a type of late-state lung cancer. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202570s000ltr.pdf
|
| 50 |
Von Hoff DD, Stephenson JJ, Jr, Rosen P, et al (2010). Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol, 20, 4877-883.
|
| 51 |
Wang Z, Gerstein M, Snyder M (2009). RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet, 10, 57-63.
DOI
|
| 52 |
Wiegand KC, Shah SP, Al-Agha OM, et al (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med, 363, 1532-43.
DOI
|
| 53 |
Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42.
DOI
ScienceOn
|
| 54 |
Zhao Q, Caballero OL, Levy S, et al (2009). Transcriptomeguided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci USA, 106, 1886-91.
DOI
|
| 55 |
Zhu CQ, Ding K, Strumpf D, et al (2010). Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol, 28, 4417-24.
DOI
|
| 56 |
Zhou YM, Liu J, Sun W (2014). MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev, 15, 1391-6.
DOI
ScienceOn
|
| 57 |
Kratz JR, He J, Van Den Eeden SK, et al (2012). A practical molecular assay to predict survival in resected nonsquamous, non-small-cell lung cancer: development and international validation studies. Lancet, 379, 823-32.
DOI
|
| 58 |
Abdulkareem IH, Blair M (2013). Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J, 54, 79-86.
DOI
|
| 59 |
Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics. CA Cancer J Clin, 60, 277-300.
DOI
|
| 60 |
Jones S, Wang TL, Shih Ie M, et al (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science, 330, 228-31.
DOI
|
| 61 |
Kobayashi S, Boggon TJ, Dayaram T, et al (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92.
DOI
|
| 62 |
Koivunen JP, Mermel C, Zejnullahu K, et al (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res, 14, 4275-83.
DOI
|
| 63 |
Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703.
DOI
|
| 64 |
Keedy VL, Temin S, Somerfield MR, et al (2011). American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 29, 2121-7.
DOI
|
| 65 |
Keedy VL, Temin S, Somerfield MR, et al (2011). American society of clinical oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 29, 2121-7.
DOI
|
| 66 |
Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703.
DOI
|
| 67 |
Rimkunas VM, Crosby KE, Li D, et al (2012). Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res, 18, 4449-57.
DOI
|
| 68 |
Pfeifer M, Grau M, Lenze D, et al (2013). PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA, 110, 12420-5.
DOI
|
| 69 |
Rosell R, Carcereny E, Gervais R, et al (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 13, 239-46.
DOI
ScienceOn
|
| 70 |
Rodig SJ, Mino-Kenudson M, Dacic S, et al (2009). Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res, 15, 5216-23.
DOI
|
| 71 |
Sun S, Schiller JH, Spinola M, et al (2007). New molecularly targeted therapies for lung cancer. J Clin Invest, 117, 2740-50.
DOI
|
| 72 |
Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6.
DOI
|
| 73 |
Shaw AT, Yeap BY, Mino-Kenudson M, et al (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harborEML4-ALK. J Clin Oncol, 27, 4247-53.
DOI
|
| 74 |
Shaw AT, Yeap BY, Solomon BJ, et al (2011). Effect of crizotinib on overall survival in patients with advanced non-smallcell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol, 12, 1004-12.
DOI
|
| 75 |
Stephens PJ, McBride DJ, Lin ML, et al (2009). Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature, 462, 1005-10.
DOI
ScienceOn
|
webmaster
